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Atrial  ﬁbrillation  (AF)  is  the  most  common  arrhythmia  in  clinical  practice  and  one  of  the
leading  cardiovascular  causes  of  hospitalization  [1,2].  Various  clinical  conditions  are  asso-
ciated  with  a  high  risk  of  developing  AF,  including  hypertension,  heart  failure,  coronary
artery  disease,  diabetes  mellitus,  and  sleep  apnoea  [3].  The  aging  of  the  population  is
another  major  cause  of  the  growing  prevalence  of  AF.  Recently,  obesity  was  reported  to
be  independently  associated  with  a  high  risk  of  developing  AF  [4—8].  This  was  conﬁrmed
in  an  experimental  animal  model  of  weight  gain  [9,10].
One  explanation  for  the  epidemiology  of  AF  is  that  the  arrhythmia  is  favoured  by
structural  and  functional  alterations  of  the  atrial  myocardium,  which  can  be  caused  by
a  multitude  of  pathogenic  factors  operating  at  different  times  during  the  natural  courseFibrillation
auriculaire  ;
Tissu  gras  cardiaque  ;
Fibrose  ;
Adipokines
of  the  arrhythmia.  This  atrial  remodelling  is  characterized  by  profound  alterations  in  the
structural  and  functional  properties  of  the  atrial  myocardium  responsible  for  the  short-
ening  of  atrial  refractoriness,  formation  of  re-entry  circuits  and  local  conduction  block
patterns  [11,12].  The  histological  remodelling  of  the  atrial  myocardium  is  central  to  the
Abbreviations: AF, atrial ﬁbrillation; EAT, epicardial adipose tissue; IL, interleukin; LA, left atrial; MMP, matrix metalloproteinase; TNF,
tumour necrosis factor.
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oxidative  stress  could  also  operate  in  this  crosstalk  between50  
athogenesis  of  AF,  notably  ﬁbrosis  [13—15].  Identiﬁca-
ion  of  the  mechanisms  underlying  the  formation  of  the
F  substrate  has  been  the  subject  of  intensive  research.
he  renin-angiotensin-aldosterone  system,  platelet-derived
rowth  factor,  connective  tissue  growth  factor  and  local
nﬂammatory  responses  secondary  to  endothelial  dysfunc-
ion  are  now  well-established  pathogenic  factors  [16—20].
he  discovery  of  a  relationship  between  the  abundance  of
trial  fatty  deposits  and  the  risk  and  severity  of  AF  brings  a
ew  potential  player  into  the  complex  scheme  of  the  patho-
hysiology  of  AF.
vidence for a relationship between
picardial fat and AF
ardiac  adipose  tissue  is  composed  of  the  pericardial  fat
ocated  outside  the  visceral  pericardium  and  the  epicar-
ial  adipose  tissue  (EAT)  situated  between  the  visceral
ericardium  and  the  epicardium  [21].  Of  note,  the  term
‘pericardial  fat’’  has  been  used  in  studies  evaluating  the
elationship  with  AF,  with  some  studies  deﬁning  epicar-
ial  fat  as  pericardial  fat  (i.e.  inside  the  pericardial  sac)
22,23],  while  others  deﬁne  pericardial  fat  as  the  sum  of
oth  epicardial  and  pericardial  adipose  tissue  [24].  In  a
tudy  involving  2317  participants  of  the  Framingham  Heart
tudy  Offspring  and  Third  Generation  Cohorts,  it  has  been
bserved  using  computed  tomography  that  the  volume  of
ericardial  fat  (adipose  tissue  within  the  pericardial  sac)
redicted  AF  risk  independent  of  other  measures  of  adi-
osity  [23].  In  another  study  using  computed  tomography
n  169  patients,  the  posterior  left  atrial  (LA)  fat  thick-
ess  (comprising  that  between  the  oesophagus,  the  main
ulmonary  artery  and  descending  thoracic  aorta)  was  asso-
iated  with  AF  burden,  independent  of  LA  area  and  body
ass  index  [25].  In  addition,  pericardial  fat  volume  is  associ-
ted  with  a  high  risk  of  AF  after  adjusting  for  traditional  risk
actors  and  LA  dilation  [22].  Similar  results  were  obtained
y  studying  pericardial  fat  via  cardiac  magnetic  resonance
maging  [24].  Peri-atrial  fat  volume,  but  not  body  mass
ndex,  is  associated  with  elevated  risk  of  AF,  indicating  that
AT  volume  may  be  more  predictive  of  the  presence  and
everity  of  AF  than  the  traditional  or  body  surface  area
easurements.  Finally,  several  studies  have  reported  that
ericardial  fat  volume  is  associated  with  AF  recurrence  after
adiofrequency  ablation  [24,26].  In  the  same  line,  domi-
ant  frequency  sites  could  be  associated  with  epicardial  fat
ocations  [27].
aracrine effects of epicardial fat on the
trial myocardium
picardial  fat  is  involved  in  lipid  and  energy  homeosta-
is;  it  is  a  source  of  free  fatty  acids  for  myocardial
nergetic  metabolism  and  may  protect  the  heart  against
oxic  levels  of  fatty  acids  [21,28—30]. Adipose  tissue
lso  produces  a  number  of  bioactive  molecules,  includ-
ng  inﬂammatory  mediators  and  adipocytokines  [31—33].
uring  ischaemic  cardiopathy,  EAT  expresses  inﬂamma-
ory  cytokines,  such  as  tumour  necrosis  factor  (TNF)-
a
r
pS.N.  Hatem
nd  interleukin  (IL)-6,  and  chemokines  such  as  monocyte
hemotactic-1  [34].  EAT  is  in  direct  contact  with  the  adja-
ent  myocardium,  allowing  paracrine  interactions  between
he  two  tissues  (cytokines  secreted  by  EAT  can  accumu-
ate  in  the  pericardial  ﬂuid)  [35].  Reduced  expression  of
ntiatherogenic  adiponectins  has  been  reported  in  EAT  from
atients  with  coronary  artery  disease,  whereas  conditioned
edia  from  the  same  patients  induced  atherogenic  changes
36].
One  explanation  for  the  relationship  between  EAT  abun-
ance  and  the  severity  of  the  arrhythmia  could  be  that
AT-secreted  adipokines  contribute  to  the  remodelling  of
he  atrial  myocardium.  This  has  been  shown  for  ﬁbrosis.
ndeed,  the  secretome  of  human  epicardial  fat,  but  not
ubcutaneous  adipose  tissue,  induces  marked  ﬁbrosis  of
he  atrial  myocardium  and  stimulates  the  transformation
f  ﬁbroblasts  into  myoﬁbroblasts,  the  source  of  extracel-
ular  matrix  components  [37].  Among  the  cytokines  found
n  abundance  in  the  EAT  secretome,  activin  A  (a  member  of
he  transforming  growth  factor-  superfamily)  and  matrix
etalloproteinases  (MMPs)  are  strong  candidates  for  the
brotic  effect  of  the  EAT  secretome.  MMPs  regulate  extra-
ellular  matrix  homeostasis,  including  the  various  collagen
bres  and  basement  membrane  components,  whereas  sev-
ral  MMPs  are  up-regulated  during  AF,  notably  MMP2  and
MP7  [17].  A  proﬁbrotic  effect  of  activin  A  has  already
een  described  for  liver  ﬁbrosis  [38—40].  Anti-activin  A  anti-
ody  neutralized  the  proﬁbrotic  effects  of  the  human  EAT
ecretome  on  the  atrial  myocardium  [37]. Activin  A  also  has
 negative  inotropic  effect  on  isolated  guinea  pig  cardiac
yocytes,  which  could  contribute  to  its  effects  on  the  atrial
yocardium  [41].
Both  activin  A  and  MMP8  are  enhanced  in  patients  with
eart  failure,  and  activin  A  is  abundantly  expressed  in
he  EAT  of  obese  patients  with  type  2  diabetes  [42].  Both
eart  failure  and  diabetes  are  well-established  risk  factors
or  AF  suggesting  a  role  of  EAT  in  these  clinical  settings.
nﬂammation  is  recognized  as  the  mechanism  underlying  the
evelopment  of  the  AF  substrate,  for  instance  in  the  context
f  pericarditis,  myocarditis  or  cardiac  surgery.  Circulating
nﬂammatory  factors  are  associated  with  the  incidence  and
revalence  of  AF  [43],  including  C-reactive  protein,  IL-6,
L-8,  IL-1 and  TNF-. All  of  these  inﬂammatory  factors
re  produced  and  secreted  by  EAT  in  abundance,  notably
uring  ischaemic  cardiopathy,  obesity  or  diabetes.  Finally,
picardial  fat  tissue  could  be  an  important  source  of  reac-
ive  oxygen  species,  for  instance  in  the  context  of  ischaemic
isease  or  post-operative  AF  [44].
onclusion
AT  appears  to  be  a  new  ‘‘player’’  in  the  formation  of  the
F  substrate.  A  paracrine  effect  on  the  neighbouring  atrial
yocardium  could  be  a  potential  mechanism  by  which  a  fat
epot  contributes  to  the  formation  of  the  arrhythmogenic
ubstrate.  Other  processes  such  as  ﬁbrofatty  inﬁltration  ordipose  tissue  and  myocardium  [12,15].  This  new  ﬁeld  of
esearch  should  lead  to  the  identiﬁcation  of  a  new  thera-
eutic  target  and  biomarkers  of  AF.
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